Ahned Fahal

Prof. Ahned Fahal


Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
EZEduard E Zijlstra
Eduard E Zijlstra
WSWendy Laureijssen-van de Sande
Wendy Laureijssen-van de Sande
OWOliverio Welsh
Oliverio Welsh
EMEl Sheikh Mahgoub
El Sheikh Mahgoub
MGMichael Goodfellow
Michael Goodfellow
Ahned FahalAhned Fahal
Ahned Fahal

1 November 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FQFlavio Queiroz-Telles
Flavio Queiroz-Telles
Ahned FahalAhned Fahal
Ahned Fahal
DFDiego Rodrigues Falci
Diego Rodrigues Falci
DCDiego H. Caceres
Diego H. Caceres
TCTom Chiller
Tom Chiller
APAlessandro C Pasqualotto
Alessandro C Pasqualotto

1 January 2004 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
Ahned FahalAhned Fahal
Ahned Fahal
Mycetoma is a chronic, granulomatous, subcutaneous, inflammatory disease caused by true fungi (eumycetoma) or filamentous bacteria (actinomycetoma). It occurs in the mycetoma belt stretching between the latitudes of 15 degrees South and 30 degrees North and is endemic in relatively arid areas. The organisms are present in the soil and may enter the subcutaneous tissue by traumatic inoculation. Mycetoma commonly affects adults aged 20 to 40 years, predominantly males. The foot is most commonly affected. Both forms of mycetoma present as a progressive, subcutaneous swelling, although actinomycetoma has a more rapid course. Multiple nodules develop which may suppurate and drain through sinuses, discharging grains during the active phase of the disease. Diagnosis may involve radiology, ultrasonic imaging, cytology, culture, histology or immunodiagnosis. Actinomycetoma is amenable to treatment by antibiotics, preferably by combined drug therapy for long periods. Eumycetoma is usually treated by aggressive surgical excision combined with medical treatment.

1 September 2004 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
AAAbdalla Oa Ahmed
Abdalla Oa Ahmed
WLWillem van Leeuwen
Willem van Leeuwen
Ahned FahalAhned Fahal
Ahned Fahal
WSWendy Laureijssen-van de Sande
Wendy Laureijssen-van de Sande
HVHenri Verbrugh
Henri Verbrugh
ABAlex van Belkum
Alex van Belkum

19 January 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
OMOriol Mitjà
Oriol Mitjà
MMMichael Marks
Michael Marks
LBLaia Bertran
Laia Bertran
KKKarsor Kollie
Karsor Kollie
DADaniel Argaw
Daniel Argaw
KAKingsley Asiedu
Kingsley Asiedu

27 March 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Ahned FahalAhned Fahal
Ahned Fahal
EMEL Sheikh Mahgoub
EL Sheikh Mahgoub
Ahned FahalAhned Fahal
Ahned Fahal
MManar Abdel-Rahman
Manar Abdel-Rahman
This communication reports on the Mycetoma Research Centre of the University of Khartoum, Sudan experience on 6,792 patients seen during the period 1991–2014.The patients were predominately young (64% under 30 years old) males (76%). The majority (68%) were from the Sudan mycetoma belt and 28% were students. Madurella mycetomatis eumycetoma was the most common type (70%). In 66% of the patients the duration of the disease was less than five years, and 81% gave a history of sinuses discharging mostly black grains (78%). History of trauma at the mycetoma site was reported in 20%. Local pain was reported in 27% of the patients, and only 12% had a family history of mycetoma. The study showed that 57% of the patients had previous surgical excisions and recurrence, and only 4% received previous medical treatment for mycetoma. Other concomitant medical diseases were reported in 4% of the patients. The foot (76%) and hand (8%) were the most commonly affected sites. Less frequently affected sites were the leg and knee (7%), thigh (2%), buttock (2%) and arm and forearm (1%). Rare sites included the chest wall, head and neck, back, abdominal wall, perineum, oral cavity, tongue and eye. Multiple sites mycetoma was recorded in 135 (2%) of cases. At presentation, 37% of patients had massive lesions, 79% had sinuses, 8% had local hyper-hydrosis at the mycetoma lesion, 11% had regional lymphadenopathy, while 6% had dilated tortuous veins proximal to the mycetoma lesions. The diagnosis of mycetoma was established by combined imaging techniques and cytological, histopathological, serological tests and grain culture. Patients with actinomycetoma received a combination of antimicrobial agents, while eumycetoma patients received antifungal agents combined with various surgical excisions. Surgical excisions in the form of wide local excision, debridement or amputation were done in 807 patients, and of them 248 patients (30.7%) had postoperative recurrence. Different types of amputations were done in 120 patients (1.7%). Many researchers consider the Sudan as the mycetoma homeland. The first report on mycetoma was at the turn of the eighteenth century, and since then many documents on mycetoma have been reported. However, there is no recent report on mycetoma in the country. In 1977 Mahgoub published data on mycetoma in Sudan, but no more data were published until the MRC was established. The present study reports on 6,792 patients with mycetoma seen and managed at the MRC in a period of 23 years. This is the largest reported number of cases on the disease at national and international levels. The clinical presentations of the reported patients were in line with the previous reports on mycetoma from the Sudan and elsewhere. Still, many patients presented late with advanced disease and enormous disabilities and deformities. Some of them had a fatal outcome due to several complications. Despite advances in the diagnosis and treatment of this disease, outcome is still unsatisfactory. There is a need for more research to develop effective treatment of mycetoma and field friendly diagnostic techniques. Adequate preventive and control measures to reduce the disease morbidity and mortality are needed.